Kure It Awards $250,000 to Kidney Cancer Immunotherapy Research in Barcelona, Spain

Orange County Nonprofit, Kure It Cancer Research, Awards International Cancer Research Grant through the American Association for Cancer Research

Dr. Ana Meseguer, of Barcelona, Spain’s Vall d’Hebron, will receive $250,000 grant to support immunotherapy kidney cancer research.

IRVINE, CA — The American Association for Cancer Research and Kure It Cancer Research are pleased to announce that Ana Meseguer, M.D., Ph. D. will receive the 2016 American Association for Cancer Research (AACR)-Kure It Cancer Research Grant for Kidney Cancer Research.

Ana, an associate professor at the Biochemistry and Molecular Biology Department in the School of Medicint of the UniversitatAutónoma de Barcelona (UAC) and co-coordinator of the Master on Translational Biomedical Research launched in 2014 by Vall d'Hebron Institut de Recerca (VHIR), will receive $250,000 during the two-year grant term.

This grant marks Kure It’s sixth grant through an AACR partnership since 2010.  AACR-Kure It grants are designed to provide support for innovative translational kidney cancer research designed to improve the survival and quality of life of patients with kidney cancer and, in turn, lead to individualized therapeutic options for the treatment or development of promising new immunotherapy kidney cancer therapies. Kure It founder Barry Hoeven recognized the AACR for assembling a team of specialists to review the submitted proposals, as well as their role in making researchers aware of the funds availaible. “The AACR partnership brought us a much larger pool of projects from which to choose, and we were pleased to be able to fund yearly awards. We are grateful to our supporters for providing consistent funding so that we can support innovative research”. 

Ana’s project, “Could TIM-1 Constitute a New Target for Renal Cell Carcinoma Immunotherapy?,” aims to investigate the presence of new immune checkpoints to increase the number of patients that could benefit from immunotherapy treatments.

“Despite the fact manipulation of the endogenous immune system has emerged as an effective anticancer therapy, there is a limitation to these treatments with a fairly small proportion of patients who achieve clinical responses” writes Dr. Meseguer, Associate Director of Translational Research at VHIR.  Dr. Meseguer and her team will work to analyze the impact of TIM-1 expression in tumor progression to improve knowledge of RCC tumor biology and target effective and personalized treatment for RCC patients. 

The expert scientific review committee, assembled by the AACR, received nine high-caliber applications from independent investigators who proposed to develop and study new immunological approaches that will have a direct application and relevance to patients with kidney cancer.

Kure It Cancer Research (www.kureit.org) was established in 2010 to fill the gap in funding and place cancer research dollars directly into the hands of the investigators. To date, Kure It Cancer Research has raised more than $4.7 million for cancer research.  With this remarkable standard of giving, Kure It is able to directly support groundbreaking research at leading cancer centers internationally.

# # #

Published on by Kure It.